// App-Quantinova.ai

P3-09-03 : A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)

Researchers

Presenter

  • Jos Manuel Prez-Garca

Principal Investigators

  • Esther Holgado

  • Giuseppe Curigliano

  • Elena Lpez Miranda

  • Jose Luis Alonso-Romero

  • Begon~a Bermejo

  • Lourdes Calvo

  • Vicente Caran~ana

  • Susana de la Cruz Sanchez

  • Maria Gion Cortes

  • Raul Marquez Vazquez

  • Aleix Prat

  • Manuel Ruiz Borrego

  • Miguel Sampayo

  • Miguel ngel Segui

  • Jesus Soberino

  • Andrea Malfettone

  • Peter Schmid

  • Javier Cortes

Medical Centers

  • IOB, Institute of Oncology, QuironSalud Group, Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), New Jersey, USA, and Barcelona, Spain

  • Hospital Arnau de Vilanova, FISABIO, Valencia, Spain; Medica Scientia Innovation Research (MedSIR), New Jersey, USA, and Barcelona, Spain

  • Hospital Universitario Ramón y Cajal, Madrid, Spain; Medica Scientia Innovation Research (MedSIR), New Jersey, USA, and Barcelona, Spain

  • European Institute of Oncology and University of Milan-Bicocca, Milan, Italy

  • Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain

  • Hospital Clinico Valencia, Valencia, Spain

  • Complejo Hospitalario Universitario de A Coruna, A Coruna, Spain

  • Hospital Arnau Vilanova, Valencia, Spain

  • Complejo Hospitalario de Navarra, Pamplona, Spain

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • MD Anderson Cancer Center, Madrid, Spain

  • Hospital Clinic i Provincial de Barcelona, Barcelona, Spain

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Medica Scientia Innovation Research (MedSIR), New Jersey, USA, and Barcelona, Spain

  • Corporacio Sanitaria i Universitaria Parc Tauli, Sabadell, Spain

  • IOB, Institute of Oncology, QuironSalud Group, Barcelona, Spain

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • IOB, Institute of Oncology, QuironSalud Group, Madrid & Barcelona, Spain; Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), New Jersey, USA, and Barcelona, Spain

Locations

  • Spain

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Programmed death-ligand 1

  • Cyclin-dependent kinase 4

  • Human epidermal growth factor receptor 2

  • Serine/threonine-protein kinase mTOR

  • tumor-infiltrating lymphocytes

  • Hormone receptor

Drug/Treatment

  • Pembrolizumab

  • Eribulin

  • taxane

Outcome

  • N/A

Study Design

  • Fixed Dose

  • Open Label

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03222856

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved